Impact of lymph node ratio in patients with stage IIIC endometrial carcinoma treated with postoperative radiotherapy

2021 ◽  
Author(s):  
Cem Onal ◽  
Sezin Yuce Sari ◽  
Guler Yavas ◽  
Ozan Cem Guler ◽  
Ecem Yigit ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Lymph Node ◽  
Lymph Node Ratio ◽  
Postoperative Radiotherapy ◽  
Progression Free Survival ◽  
Stage Iiic ◽  
Factors Affecting ◽  
Study Results ◽  
Node Ratio ◽  
Cervical Stromal Invasion

Aim: To evaluate the prognostic value of the lymph node ratio (LNR) and other clinicopathological factors in patients with stage IIIC endometrial cancer. Methods: Factors affecting overall survival (OS) and progression-free survival (PFS) were assessed in 397 patients with stage IIIC endometrial cancer treated with postoperative radiotherapy. Patients undergoing the removal of at least ten lymph nodes were included in the study. Results: The 5-year OS and PFS rates were 58% and 52%, respectively, with a median follow-up time of 35.7 months. The LNR cutoff value was 9.6%. In the multivariate analysis, advanced age (≥60 years), grade III tumor, presence of cervical stromal invasion, higher LNR and lack of adjuvant chemotherapy were independent predictors for worse OS and PFS. Conclusion: The LNR is an independent predictor for OS and PFS in patients with stage IIIC endometrial cancer treated with postoperative radiotherapy.

Impact of lymph node ratio and clinico-pathologic parameters on stage IIIC endometrial cancer prognosis: A validation study

2012 ◽  
Vol 125 ◽  
pp. S146-S147
Author(s):  
S. Polterauer ◽  
S. Khalil ◽  
O. Zivanovic ◽  
N. Abu-Rustum ◽  
A. Reinthaller ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Lymph Node ◽  
Validation Study ◽  
Lymph Node Ratio ◽  
Cancer Prognosis ◽  
Stage Iiic ◽  
Node Ratio ◽  
Pathologic Parameters

Prognostic Value of Lymph Node Ratio and Clinicopathologic Parameters in Patients Diagnosed With Stage IIIC Endometrial Cancer

2012 ◽  
Vol 119 (6) ◽  
pp. 1210-1218 ◽  
Author(s):  
Stephan Polterauer ◽  
Susan Khalil ◽  
Oliver Zivanovic ◽  
Nadeem R. Abu-Rustum ◽  
Gerda Hofstetter ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Lymph Node ◽  
Prognostic Value ◽  
Lymph Node Ratio ◽  
Stage Iiic ◽  
Node Ratio ◽  
Clinicopathologic Parameters

scholarly journals Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Kabsoo Shin ◽  
Se Jun Park ◽  
Jinsoo Lee ◽  
Cho Hyun Park ◽  
Kyo Young Song ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Lymph Node ◽  
Adjuvant Chemotherapy ◽  
Prognostic Value ◽  
Lymph Node Ratio ◽  
Node Dissection ◽  
Stage Iiic ◽  
Node Ratio ◽  
N Stage ◽  
N Staging

Abstract Background We sought to assess the prognostic significance of lymph node ratio (LNR) and N stage in patients undergoing D2 gastrectomy and adjuvant chemotherapy, S-1, and XELOX and to compare the efficacy of them according to LNRs and N stages to evaluate the clinical impact of using LNRs compared with using N staging. Methods Patients undergoing D2 gastrectomy with adequate lymph node dissection and adjuvant chemotherapy for stage II/III gastric cancer between Mar 2011 and Dec 2016 were analysed. Of the 477 patients enrolled, 331 received S-1 and 146 received XELOX. LNR groups were segregated as 0, 0–0.1, 0.1–0.25, and > 0.25 (LNR0, 1, 2, and 3, respectively). Propensity score matching (PSM) was used to minimise potential selection bias and compare DFS and OS stratified by LNRs and N stages in the two treatment groups. Results After PSM, the sample size of each group was 110 patients, and variables were well balanced. All patients had more than 15 examined lymph nodes (median 51, range 16~124). In multivariate analysis, LNR (> 0.25) and N stage (N3) showed independent prognostic value in OS and DFS, but LNR (> 0.25) showed better prognostic value. In subgroup analysis, the LNR3 group showed better 5-year DFS (20% vs 54%; HR 0.29; p = 0.004) and 5-year OS (26% vs 67%; HR 0.28; p = 0.020) in the XELOX group. The N3 group showed better 5-year DFS (38% vs 66%; HR 0.40; p = 0.004) and 5-year OS (47% vs 71%; HR 0.45; p = 0.019) in the XELOX group. Stage IIIC showed better 5-year DFS (22% vs 57%; HR 0.32; p = 0.004) and 5-year OS (27% vs 68%; HR 0.32; p = 0.009) in the XELOX group. The LNR3 group within N3 patients showed better 5-year DFS (21% vs 55%; HR 0.31; p = 0.004) and 5-year OS (27% vs 68%; HR 0.34; p = 0.018) in the XELOX group. Conclusions LNR showed better prognostic value than N staging. LNR3, N3 and stage IIIC groups showed the superior efficacy of XELOX to that of S-1. And the LNR3 group within N3 patients showed more survival benefit from XELOX. LNR > 0.25, N3 stage and stage IIIC were the discriminant factors for selecting XELOX over S-1. Trial registration Not applicable (retrospective study).

Sign in / Sign up

Export Citation Format

Share Document